Abstract The Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) was
developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease …

The use of Disease progression models (DPMs) in Drug Development has been widely
adopted across therapeutic areas as a method for integrating previously obtained disease …

Background Progressive supranuclear palsy (PSP) is a neurodegenerative, late‐onset
disease that is challenging in terms of assessment. The Progressive Supranuclear Palsy …

Degenerative cerebellar ataxias comprise a heterogeneous group of rare and ultra‐rare
genetic diseases. While disease‐modifying treatments are now on the horizon for many …

Introduction As currently used, the Alzheimer's Disease Assessment Scale-Cognitive
subscale (ADAS-Cog) has low sensitivity for measuring Alzheimer's disease progression in …

Analyzing the progression of Alzheimer's disease (AD) is challenging due to lacking
sensitivity in currently available measures. AD stages are typically defined based on …

Background Longitudinal item response theory (IRT) models previously suggested that the
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) motor …

There is strong interest in developing predictive models to better understand individual
heterogeneity and disease progression in Alzheimer's disease (AD). We have built upon …

Background The outcome of clinical trials in neurodegeneration can be highly uncertain due
to the presence of a strong placebo effect. Objectives To develop a longitudinal model that …

Purpose This manuscript aims to precisely describe the natural disease progression of
Parkinson's disease (PD) patients and evaluate approaches to increase the drug effect …